with filter limits set to retrieve "full-text" and "English" literature. Studies from both sources were considered for inclusion if, 1) the ethnicity of the population was clearly indicated; 2) either allele frequencies or alleles for HLA-B genotypes were reported; 3) the method by which HLA-B
was genotyped was reliable and proven; 4) the sample population consisted of at least 50 individuals; 5) the study represented publication of novel data, not literature reviews or metaanalyses of previously published data; and 6) the population studied did not have a concomitant disease (such as an autoimmune condition) that would be expected to result in a distribution of HLA-B alleles that were different from the general population. In instances where genotype data from large cohorts of ethnically-diverse individuals were reported without respect to ethnicity, studies were only considered if one ethnicity was ≥95% of the majority. In some cases, sample sizes or allele frequencies were updated to reflect only subjects successfully genotyped for HLA-B (rather than the total sample size of the study) or to correct errata in the original publication. Tables S1 and S2 ).
Other Considerations

HLA-A*31:01
HLA-A*31:01 has also been associated with carbamazepine hypersensitivity reactions (1, 2) .
This includes not only SJS and TEN (3, 4) , but also other phenotypes including maculopapular It is unclear why the severity of the cutaneous adverse drug reactions associated with the two alleles differ (2) . It is also unclear why the HLA-A*31:01 association is found in more populations than the HLA-B*15:02 association. It may be related to the fact that the background frequency of the HLA-A*31:01 allele is higher than the HLA-B*15:02 allele in many populations. The frequency of HLA-B*15:02 is extremely low in the Japanese, Korean and European populations, ranging from (0.002 -0.02) (2) .
Other AntiepilepticsWithAn Aromatic Ring
Several drugs structurally and therapeutically similar to carbamazepine have also been associated with drug-induced adverse cutaneous reactions and HLA-B*15:02.
Phenytoinand fosphenytoin, the parenteral prodrug of phenytoin, are FDA approved for the treatment of tonic-clonic seizures, partial seizures, statusepilepticus and for seizure prevention.
Positive HLA-B*15:02 has been reported to occur less frequently in phenytoin/fosphenytoininduced Stevens-Johnson Syndrome (SJS) / toxic epidermal necrolysis (TEN) than in carbamazepine-induced SJS/TEN though this is supported currently by only limited data (9) (10) (11) .
Oxcarbazepine is the keto-analog of carbamazepine. As with carbamazepine, oxcarbazepine has been used in the treatment of partial seizures with and without generalization and in the treatment of neuropathic pain. As of this report, three cases have been reported of oxcarbazepine-induced SJS in individuals positive for HLA-B*15:02 (12) (13) (14) . There is also one case report tying oxcarbazepine to MPE without progression to SJS/TEN in a patient of Han Chinese decent (15) .
Eslicarbazepine acetate is an antiepileptic drug used in Europe and America. It is a prodrug which is activated to eslicarbazepine, an active metabolite of oxcarbazepine. As of this report, there have been no cases reported of eslicarbazepine-induced SJS/TEN; however, based on its structural similarity to oxcarbazepine, caution should be used in susceptible individuals positive for HLA-B*15:02.
Lamotrigine has been associated with SJS/TEN, particularly with rapid dose escalation or when used in combination with valproic acid. There are conflicting reports regarding its association with HLA-B*15:02. In one study of three lamotrigine-induced SJS in a Han Chinese population, none were associated with HLA-B*15:02 (16) , but in a separate study in the same population, two of the six lamotrigine-induced SJS were positive for HLA-B*15:02 (17) .
Available Genetic Test Options and Interpretation
Commercially available genetic testing options change over time. Information that may assist in evaluating options is available below, as well as on the Pharmacogenetic Tests section Figure S1 and reported as the diplotype of both HLA-B alleles.
Genotyping is another common approach in which the sequence variants that define HLA-B Another option is the genotyping of one or more single nucleotide polymorphisms (SNPs) that are near the HLA-B locus and in linkage disequilibrium with the HLA-B*15:02 allele. However, as this test is indirect and depends upon linkage disequilibrium which may vary between different populations, it may have lower accuracy. It also requires genotyping and may not be any faster or less expensive than genotyping of the specific defining variants.
Levels of Evidence
Supplemental Table S3 summarizes Overall, the dosing recommendations are simplified to allow rapid interpretation by clinicians.
We chose to use a slight modification of a transparent and simple system for just three categories for recommendations adopted from the rating scale for evidence-based recommendations on the Figure S2 .Amino acid sequence alignment of HLA-B*15:02 and the reference sequence. Amino acid differences between the two sequences are highlighted in blue. This alignment was generated using the IMGT/HLA Database's alignment tool (www.ebi.ac.uk/imgt/hla/align.html) and visualized in Jalview. (78) 
